◼ Archived
Business
New tumor cases show common gene therapy tool can come with risk
The FDA launches an investigation into Novartis' Zolgensma gene therapy following reports of new tumor cases.
Endpoints News
8 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
Treasury's COINS rule draft would narrow the path for China biotech dealmaking, experts say
6 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
"The beginning of a new scientific paradigm": Zuckerberg's Biohub, U.S. and Google build virtual cell
Zuckerberg's Biohub expands its virtual cell initiative to $1.8 billion with Meta, Google, and Isomorphic.
◼ Archived
Business
AstraZeneca hopes to ‘achieve amazing things’ with new Kendall Square R&D center
1 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
◼ Archived
Business
Novartis takes rights to Abogen’s mRNA T cell engager for $575M upfront
Novartis secures the rights to Abogen’s mRNA T cell engager in a massive $575 million upfront transaction.
◼ Archived
Business
Biotech's most exciting startups of 2026: Meet this year's Endpoints 11
Endpoints News has revealed the 2026 Endpoints 11, spotlighting the most exciting startups currently shaping the biotechnology landscape.
◼ Archived
Business
🔮 fades ✓
Takeda’s long-serving R&D chief Andy Plump to retire in wake of pipeline successes
Takeda Pharmaceutical's R&D chief Andy Plump is set to retire in June 2027 following a period of significant pipeline reorganization and regulatory success.
◼ Archived
Health
🔮 fades ✓
Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T
Coverage reveals a third death in opaque Chinese clinical trials involving CAR-T therapy, intensifying global scrutiny.